Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Vaxigrip Tetra Quadrivalent influenza vaccine (split virion, inactivated) 0.5mL suspension for injection 2022 (International Presentation)
Section 19A approved medicine
(Approval lapsed) Vaxigrip Tetra Quadrivalent influenza vaccine (split virion, inactivated) 0.5mL suspension for injection 2022 (International Presentation)
Section 19A approval holder
Sanofi-Aventis Australia Pty Ltd ABN: 31 008 558 807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
VAXIGRIP TETRA Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus HA 60 mcg 0.5 mL suspension for injection
Indication(s)
Vaxigrip Tetra is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for:
- active immunisation of adults, including pregnant women, and children from 6 months of age and older
- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women
Images
